OPPORTUNITY: a randomized clinical trial of growth hormone on outcome in hemodialysis patients.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

The mortality rate of maintenance hemodialysis (MHD) patients remains high.

Who Took Part

The study group was 2500 patients.

The age groups tagged for this paper are adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and multicenter.

The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

Some patients received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

More than one site took part, so the patients came from several places.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Exercise Tolerance, Human Growth Hormone, Hypoalbuminemia, Inflammation Mediators, Injections and Kidney Failure, Chronic.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 2500 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 1 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2008 (Clinical journal of the American Society of Nephrology : CJASN), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.